Technical Articles

基于TR-FRET技术的PCSK9抑制剂在缺血性卒中防治中的研究进展
Research Advances in PCSK9 Inhibitors Based on TR-FRET Technology for the Prevention and Treatment of Ischemic Stroke
发布时间 2026-04-10
PCSK9 is primarily synthesized and secreted by the liver as a serine protease, playing a crucial role in maintaining cholesterol homeostasis. PCSK9 elevates LDL-C levels by inhibiting circulating LDLR, competitively binding to LDLR on the surface of hepatocytes to form a PCSK9/LDLR complex. This complex is then transported into the cell via vesicles and degraded by lysosomes, leading to increased plasma LDL-C levels.
View details
  • Neuroscience
  • TR-FRET Technology
  • PCSK9-LDLR
  • Ischemic Stroke
Total 1
  • 1
Go to